Investigating how a specific enzyme affects cocaine use disorder in brain cells
Defining the cell-type specific role of histone acetyltransferase KAT2a in nucleus accumbens D1 medium spiny neurons as a driver of cocaine use disorder
['FUNDING_FELLOWSHIP'] · VANDERBILT UNIVERSITY · NIH-10830266
This study is looking at how a certain enzyme in brain cells might influence addiction to cocaine, with the hope of finding new ways to help people struggling with cocaine use disorder.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VANDERBILT UNIVERSITY (nih funded) |
| Locations | 1 site (Nashville, UNITED STATES) |
| Trial ID | NIH-10830266 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of a specific enzyme, KAT2a, in brain cells that are involved in cocaine use disorder (CUD). By studying how this enzyme affects the behavior of dopamine receptor-expressing neurons in the nucleus accumbens, the research aims to uncover the molecular mechanisms that lead to addiction. The approach includes detailed proteomic and bioinformatic analyses to identify changes in gene expression related to cocaine exposure. The findings could provide insights into potential new treatments for CUD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals struggling with cocaine use disorder who may benefit from new treatment options.
Not a fit: Patients who do not have a history of cocaine use or those with other substance use disorders unrelated to cocaine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new pharmacotherapies for cocaine use disorder.
How similar studies have performed: Previous research has shown promising results in understanding the molecular mechanisms of addiction, but this specific approach focusing on KAT2a is relatively novel.
Where this research is happening
Nashville, UNITED STATES
- VANDERBILT UNIVERSITY — Nashville, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: EMERSON, SOREN D — VANDERBILT UNIVERSITY
- Study coordinator: EMERSON, SOREN D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.